Results

Eisai Co. Ltd.

11/29/2021 | Press release | Distributed by Public on 11/28/2021 17:38

European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell CarcinomaApproval Based on[...]

News release searchSearch